Inventor · disambiguated record

Chengfei Pu

Also filed as: PU CHENGFEI

28 granted patents·29 pending applications·62 citations·filing 2017–2025

94Inventor score

Technology areasA61K C07K C12N A61P C12Y

Files withINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD45 INNOVATIVE CELLULAR THERAPEUTICS CO LTD11 INNOVATIVE CELLULAR THERAPEUTICS INC1

Top patents by PatentIndex Score

57 records

0196US11104732B2Reducing immune inhibition induced by SIGLEC-15INNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2020·Granted Aug 31, 2021·6 cites·22 claims
0295US10869888B2Modified cell expansion and uses thereofINNOVATIVE CELLULAR THERAPEUTICS CO LTD·Filed 2019·Granted Dec 22, 2020·10 cites·28 claims
0395US10561686B2Modified cell expansion and uses thereofINNOVATIVE CELLULAR THERAPEUTICS CO LTD·Filed 2018·Granted Feb 18, 2020·17 cites·9 claims
0495US9932405B2Use of chimeric antigen receptor modified cells to treat cancerINNOVATIVE CELLULAR THERAPEUTICS CO LTD·Filed 2017·Granted Apr 3, 2018·13 cites·8 claims
0594US10493139B2Humanized anti-CD19 antibody and use thereof with chimeric antigen receptorINNOVATIVE CELLULAR THERAPEUTICS CO LTD·Filed 2018·Granted Dec 3, 2019·9 cites·5 claims
0688US10793638B2Use of chimeric antigen receptor modified cells to treat cancerINNOVATIVE CELLULAR THERAPEUTICS CO LTD·Filed 2018·Granted Oct 6, 2020·2 cites·15 claims
0787US10918667B2Modified cell expressing therapeutic agent and uses thereofINNOVATIVE CELLULAR THERAPEUTICS CO LTD·Filed 2019·Granted Feb 16, 2021·2 cites·14 claims
0884US11690874B2Use of chimeric antigen receptor modified cells to treat autoimmune diseaseINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2019·Granted Jul 4, 2023·2 cites·11 claims
0982US2024218075A1Use of chimeric antigen receptor modified cells to treat cancerINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2024·Application pending·0 cites
1081US2025188146A1Modified Cell Expansion and Uses ThereofINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2024·Application pending·0 cites
1179US12297267B2Humanized anti-CD19 antibody and use thereof with chimeric antigen receptorINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2022·Granted May 13, 2025·0 cites·16 claims
1278US11566223B2Chimeric antigen receptor cell preparation and uses thereofINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2018·Granted Jan 31, 2023·1 cites·21 claims
1376US11364289B2Humanized anti-CD19 antibody and use thereof with chimeric antigen receptorINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2019·Granted Jun 21, 2022·0 cites·12 claims
1476US2025025506A1Engineered safety in cell therapyINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2024·Application pending·0 cites
1572US12150960B2Modified cell expansion and uses thereofINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2020·Granted Nov 26, 2024·0 cites·7 claims
1672US2025171560A1Chimeric antigen receptor cells for treating solid tumorINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2024·Application pending·0 cites
1771US11932700B2Use of chimeric antigen receptor modified cells to treat cancerINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2020·Granted Mar 19, 2024·0 cites·9 claims
1871US11834502B2Reducing immune inhibition induced by SIGLEC-15INNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2021·Granted Dec 5, 2023·0 cites·19 claims
1970US12240915B2Chimeric antigen receptor cells for treating solid tumorINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2019·Granted Mar 4, 2025·0 cites·19 claims
2069US11161913B2Chimeric antigen receptor cells for treating solid tumorINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2021·Granted Nov 2, 2021·0 cites·13 claims
2168US12076343B2Engineered safety in cell therapyINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2021·Granted Sep 3, 2024·0 cites·20 claims
2268US11981920B2Modified cell with enhanced migration capabilityINNOVATIVE CELLULAR THERAPEUTICS CO LTD·Filed 2019·Granted May 14, 2024·0 cites·15 claims
2368US11633427B2Vaccine and uses thereof in cell therapyINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2022·Granted Apr 25, 2023·0 cites·8 claims
2468US2023226113A1Vaccine and Uses thereof in Cell TherapyINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2023·Application pending·0 cites
2568US2022339193A1Modified Cell Expressing Therapeutic Agent and Uses thereofINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2022·Application pending·0 cites
2666US11701385B2Modulation of cell function for immunotherapyINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2019·Granted Jul 18, 2023·0 cites·14 claims
2765US2022000921A1Modified Cell Expressing Therapeutic Agent and Uses thereofINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2019·Application pending·0 cites
2864US2024199760A1Nanobody Target MSLN and Uses in Chimeric Antigen Receptor Cell TherapyINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2023·Application pending·0 cites
2963US2024058337A1Managing Side Effects in T Cell TherapyINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2023·Application pending·0 cites
3063US2025121005A1CAR and Polyspecific Binding Molecules Targeting Solid TumorsINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2023·Application pending·0 cites
3162US11235004B2Lymphocyte cell lines and uses thereofINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2018·Granted Feb 1, 2022·0 cites·26 claims
3262US2021161961A1Modified Cell Expressing Therapeutic Agent and Uses thereofINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2021·Application pending·0 cites
3361US2024075061A1Cell therapy activating lymphocyte in tmeINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2022·Application pending·0 cites
3461US2024299452A1Rapamycin and Cell TherapyINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2024·Application pending·0 cites
3559US12043654B2Anti-GCC antibody and CAR thereof for treating digestive system cancerINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2021·Granted Jul 23, 2024·0 cites·21 claims
3659US11833174B2Modified cell with enhanced functionality and cellular therapy thereofINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2020·Granted Dec 5, 2023·0 cites·17 claims
3759US11739136B2Inducible dominant negative PD-1 and uses in adoptive cell therapyINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2020·Granted Aug 29, 2023·0 cites·11 claims
3859US10654934B2Use of chimeric antigen receptor modified cells to treat cancerINNOVATIVE CELLULAR THERAPEUTICS CO LTD·Filed 2018·Granted May 19, 2020·0 cites·33 claims
3959US2023227779A1Enhanced Chimeric Antigen Receptor Cells in Hypoxic Tumor MicroenvironmentINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2023·Application pending·0 cites
4058US11788072B2Activation of APC in immunotherapyINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2020·Granted Oct 17, 2023·0 cites·18 claims
4157US11866494B2CAR T therapy through uses of co-stimulationINNOVATIVE CELLULAR THERAPEUTICS CO LTD·Filed 2019·Granted Jan 9, 2024·0 cites·9 claims
4257US2024269182A1Modified Chimeric Antigen Receptor and Use thereofINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2022·Application pending·0 cites
4355US11858977B2Modified TCR and uses thereofINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2020·Granted Jan 2, 2024·0 cites·18 claims
4454US2021379149A1Increasing or Maintaining T-Cell Subpopulations in Adoptive T-Cell TherapyINNOVATIVE CELLULAR THERAPEUTICS CO LTD·Filed 2019·Application pending·0 cites
4553US2023201258A1Polyspecific Binding Molecules and their use in Cell TherapyINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2021·Application pending·0 cites
4652US2023322899A1Fusion protein enhancing cell therapyINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2021·Application pending·0 cites
4752US2021060069A1Coupled redirected cells and uses thereofINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2020·Application pending·0 cites
4852US2024024476A1CAR Cells and Polyspecific Binding Molecules for Treating Solid TumorINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2022·Application pending·0 cites
4952US2021100841A1Presenting cell and use thereof in cell therapyINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2020·Application pending·0 cites
5052US2021137983A1Nk cell expansion and uses thereofINNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD·Filed 2020·Application pending·0 cites

Showing the top 50 of 57 patent records by PatentIndex Score.

Join the waitlist — get patent alerts

Get an alert when Chengfei Pu files or is granted a new patent.

We store only your email — no account needed. See our privacy policy.

Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →